Home » Stocks » SAGE

Sage Therapeutics, Inc. (SAGE)

Stock Price: $43.73 USD -0.40 (-0.91%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
Market Cap 2.56B
Revenue (ttm) 1.11B
Net Income (ttm) 637.05M
Shares Out 58.37M
EPS (ttm) 11.66
PE Ratio 3.75
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $43.73
Previous Close $44.13
Change ($) -0.40
Change (%) -0.91%
Day's Open 43.80
Day's Range 43.67 - 44.93
Day's Volume 888,959
52-Week Range 42.85 - 98.39

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 days ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...

1 week ago - Business Wire

Several drugmakers have important clinical trial updates on the way.

Other stocks mentioned: BIIB, NVS, PFE, QURE, RHHBY
3 weeks ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...

3 weeks ago - Business Wire

These are the stocks seeing the most insider buying this week

YouTube video

Brian Sullivan brings you the top five stocks seeing the most insider buying action this week, on Worldwide Exchange with data from Insiderscore.com.

Other stocks mentioned: ASAN, CLR, EVA, QSR
1 month ago - CNBC Television

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...

1 month ago - Business Wire

Sage has been struggling for some time to bring its flagship antidepressant to the market.

1 month ago - The Motley Fool

The neuroscience-focused biotech company didn't give investors the result they wanted.

1 month ago - The Motley Fool

Searching for undervalued biotech stocks? Here are 4 biotech stocks to buy for a mix of value and growth in any portfolio.

Other stocks mentioned: BIIB, INVA, SIGA
1 month ago - InvestorPlace

Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.

Other stocks mentioned: BIIB, NERV, VTGN
1 month ago - Zacks Investment Research

Long-awaited clinical trial results weren't as successful as hoped.

1 month ago - The Motley Fool

Sage Therapeutics Inc (NASDAQ: SAGE) said on Tuesday its candidate drug for depression that it developed in collaboration with Biogen Inc was found effective in alleviating the symptoms, as per the resu...

1 month ago - Invezz

The shares of Sage Therapeutics Inc (NASDAQ:SAGE) are down 16.5% to trade at $60.85 at last check, following lackluster Phase 3 test results for the biotechnology company's depression drug, Zuranolone.

1 month ago - Schaeffers Research

Looking to make a comeback after a big Phase 3 flop, Sage Therapeutics Inc (NASDAQ: SAGE) revealed data from another Phase 3 evaluating zuranolone in patients with Major Depressive Disorder (MDD). Thoug...

1 month ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilita...

1 month ago - Business Wire

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have announced data from WATERFALL Phase 3 study evaluating zuranolone (SAGE-217/BIIB125) in patients with Major Depressive Disorder (M...

1 month ago - Benzinga

Binary events expected this month could have enormous implications for these drugmakers and their shareholders.

Other stocks mentioned: BIIB, VRTX
1 month ago - The Motley Fool

A first-of-its-kind medical device from a top-10 biotech could change medical cannabis consumption.

Other stocks mentioned: CGC, CURLF, MRK, TRSSF
2 months ago - The Motley Fool

Investors need to pay close attention to Sage Therapeutics (SAGE) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (Nasdaq:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitat...

2 months ago - Business Wire

Investors need to pay close attention to Sage Therapeutics (SAGE) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilita...

2 months ago - Business Wire

As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year. The post 7 of the Best Pharma Stocks to Buy Now appeared first on ...

Other stocks mentioned: ALLK, HZNP, IBRX, IMAB, MNMD, SWTX
2 months ago - InvestorPlace

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 17.17% and -18.78%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people ...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...

3 months ago - Business Wire

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have scored their first but narrow win after signing their $3.1 billion deal last year in November. SAGE-324, the second major molecule...

Other stocks mentioned: BIIB
3 months ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatmen...

Other stocks mentioned: BIIB
3 months ago - Business Wire

Gilead Sciences, Biogen and Vertex Pharmaceuticals could top expectations in an otherwise soft quarter for biotech stocks, an analyst said Thursday. He sees key products beating forecasts.

Other stocks mentioned: BIIB, GILD, VRTX
3 months ago - Investors Business Daily

Investors need to pay close attention to Sage Therapeutics (SAGE) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

When stocks are punished, it's not always for a good reason.

Other stocks mentioned: BIIB, CCL, CCR, LL, SKY, VIAC
3 months ago - GuruFocus

Though these stocks have dropped, upcoming news offers hope for them to rebound.

Other stocks mentioned: BLUE, TRIL
4 months ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...

4 months ago - Business Wire

Other stocks mentioned: BIO, INVA
4 months ago - GuruFocus

Can this brain health-focused biotech continue to rise, or will it fade -- again?

4 months ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported complete 12-month data from the 30 mg cohort and interim data from the 50 mg cohort of the ongoing Phase 3 open-l...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilita...

4 months ago - Business Wire

A Relative Strength Rating upgrade for Sage Therapeutics shows improving technical performance. The post Sage Therapeutics Shows Rising Price Performance With Jump To 81 RS Rating appeared first on Inve...

5 months ago - Investors Business Daily

With the trading day more than halfway over, the broad markets saw a huge pull back on Thursday.

Other stocks mentioned: EXPE, MAT, T, URBN, CME, CP, GBT ...
5 months ago - 24/7 Wall Street

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the ...

5 months ago - Business Wire

Sage Therapeutics, Inc. (SAGE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives o...

5 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives o...

5 months ago - Business Wire

American BriVision: Deep Dive Into Market Potential

Other stocks mentioned: ABVC, BIIB, KMDA, MRK, SGEN
6 months ago - Seeking Alpha

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives o...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives o...

7 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of peop...

7 months ago - Business Wire

Naughty or nice, shareholders aren't getting anything on their wish lists from these stocks this year.

Other stocks mentioned: BLUE, GLPG
7 months ago - The Motley Fool

Biogen recently announced a $1.5 billion collaboration agreement with Sage Therapeutics. Despite an earlier failed trial, Zuranolone is a promising therapy for depression.

Other stocks mentioned: BIIB
7 months ago - Seeking Alpha

About SAGE

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a compound that is in Phase II clinical ... [Read more...]

Industry
Biotechnology
IPO Date
Jul 18, 2014
CEO
Jeffrey Jonas
Employees
298
Stock Exchange
NASDAQ
Ticker Symbol
SAGE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 22 analysts, the average rating for SAGE stock is "Buy." The 12-month stock price forecast is 91.26, which is an increase of 108.69% from the latest price.

Price Target
$91.26
(108.69% upside)
Analyst Consensus: Buy